Posted by Michael Wonder on 31 Mar 2026
Savara announces EMA validation of marketing authorisation application for Molbreevi in auto-immune pulmonary alveolar proteinosis
30 March 2026 - Savara today announced that the EMA has validated the submission of the Molbreevi marketing authorisation application in auto-immune pulmonary alveolar proteinosis; the submission will now be reviewed by the CHMP.
EMA review of Molbreevi marketing authorisation application has now initiated, decision expected in Q1, 2027.
